Dr Kim - Allogeneic transplant in myeloma & GvHD 

Dennis Kim, MD, PhD.
Oncologist/Hematologist
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Allogeneic hematopoietic stem cell transplantation is still a potential therapeutic option for myeloma although it is nowadays used very rarely in the clinic. However, multiple studies suggested that graft-versus-myeloma effect could potentially eradicate myeloma clones following allogeneic hematopoietic stem cell transplantation.
In this presentation, we will discuss overview of the principle of allogeneic hematopoietic stem cell transplantation, current trend of its usage as well as post-transplant complications, particularly on the graft-versus-host disease and its pathogenesis, clinical presentation and its management. Also, we will discuss shortly about the contemporary indication of allogeneic transplantation for myeloma treatment.